Physician profile
Stephanie Sullivan
NPI 1902197288
$4,881.18
in general payments reported to CMS, 2019-2025
23 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.46 · 2021: $101 · 2022: $111 · 2023: $1,485 · 2024: $1,932 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,055.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $781.17 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Reflexion Medical, INC. | $600.00 | 2023 | Reflexion Medical Radiotherapy System |
| Glaxosmithkline, LLC. | $550.42 | 2023-2025 | Jemperli, Zejula |
| Eisai INC. | $502.54 | 2023-2025 | |
| Abbvie INC. | $485.11 | 2024-2025 | |
| Intuitive Surgical, INC. | $374.14 | 2022-2024 | |
| Myriad Genetic Laboratories, INC. | $338.75 | 2023-2025 | Myrisk, Precisetumor |
| Astrazeneca Pharmaceuticals LP | $299.11 | 2023-2025 | Lynparza |
| Immunogen, INC. | $141.20 | 2023-2024 | Elahere, Elahere |
| Baxter Healthcare | $128.62 | 2024-2025 | Tisseel, Perclot |
| Tempus Ai, INC | $127.95 | 2024 | |
| Novo Nordisk INC | $101.39 | 2021 | |
| Caris Mpi, INC. | $77.63 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $67.77 | 2024-2025 | |
| Daiichi Sankyo INC. | $55.97 | 2024 | Enhertu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $50.96 | 2025 | 3dimensions |
| Astellas Pharma US INC | $45.73 | 2023-2025 | Veozah |
| Verastem, INC. | $33.35 | 2025 | Avmapki Fakzynja Co-Pack |
| Smith+Nephew, INC. | $32.29 | 2024 | Stravix Pl |
| Stryker Corporation | $24.58 | 2023 | N/A |
| Seagen INC. | $23.92 | 2023 | Tivdak |
| Medtronic, INC. | $20.63 | 2024 | Ligasure |
| Hologic Sales and Service, LLC | $17.95 | 2023 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.